摘要
目的探讨孟鲁司特治疗支气管哮喘对患者免疫反应的影响，为临床治疗提供依据。方法选择支气管哮喘患者104例，采用数字表法随机分为治疗组和对照组，两组各52例，对照组患者进行常规治疗，治疗组在对照组基础上应用孟鲁司特治疗。评估两组患者治疗前后日间症状、夜间症状，应用初期呼吸阻力（Rrsc）和反应阈值（Dmin）评估气道反应性，检测治疗前后T淋巴细胞亚群的变化。结果治疗组治疗后日间症状评分、夜间症状评分和Rrsc分别为（0．49±0．12）分、（0．66±0．20）分和（2．19±0．38）cmH2O，均低于对照组治疗后（t=7．90、8．13、8．24，均P〈0．05），两组治疗后均低于治疗前，差异均有统计学意义（t=9．38、8．66、9．17，9．41、8．90、9．24，均P〈0．05）；治疗组治疗后Dmin为（8．29±0．44）U，高于对照组治疗后，两组治疗后均高于治疗前，差异均有统计学意义（t=7．41、8．23，均P〈0．05）；治疗组治疗后CD4和CD4／CD8＋分别为（43．03±5．02）％和（1．79±0．34），均高于对照组治疗后（t=9．81、10．04，均P〈0．05），两组治疗后均高于治疗前，差异均有统计学意义（t=10．62、10．33，10．93、10．62，均P〈0．05）；治疗组治疗后CD8为（23．38±3．88）％，低于对照组治疗后（t=9．93，P〈0．05），两组治疗后均低于治疗前，差异有统计学意义（t=9．16、9．29，P〈0．05）。结论君鲁司特治疗支气管哮喘能够显著改善患者症状和免疫功能，值得临床推广应用。
Objective To explore the influence of Montelukast in the treatment of patients with bronchial asthma on the immune response, and to provide the basis for clinical treatment. Methods 104 patients with bronchial asthma were selected. They were randomly divided into the treatment group and the control group by the random number table method,with 52 cases in each group. The control group patients were given conventional treatment, and the treatment group were treated with Montelukast on the basis of the control group. Daytime symptom and night symptom of the two groups before and after treatment were assessed, and airway reactivity by the early respiratory resistance （Rrsc） and response threshold （Dmin） were evaluated. And the change of T lymphocyte subsets before and after the treatment were detected. Results The day symptom scores, night symptom scores and Rrsc of the treatment group after treatment were respectively （ 0.49 ± 0.12 ） points, （ 0. 66 ± 0.20 ） points and （ 2.19 ±0.38 ） cmH2O, which were lower than those of the control group after treatment （ t = 7.90,8.13,8.24, all P 〈 0.05 ）. The data of the two groups after treatment were lower than those before treatment, the differences were statistically significant （ t = 9.38,8.66, 9. 17,9.41,8.90,9.24, all P 〈 0.05 ）. Dmin of the treatment group after treatment was （8.29 ±0.44） U, which was higher than that of the control group after treatment, the data of the two groups after treatment were higher than those before the treatment, the differences were statistically significant （ t = 7.41,8.23, all P 〈 0.05 ）. CD4 and CD4＋/CDs of the treatment group after treatment were （43.03 ± 5.02 ）% and （ 1.79 ± 0.34 ）, respectively, which were higher than those of the control group after treatment （ t = 9.81,10.04, all P 〈 0.05 ）. The data of the two groups after treatment were higher than those before the treatment, the differences were statistically significantly different （ t = 10. 62,10.33, 10. 93,10.62, all P 〈 0.05 ）. CDs of the treatment group after treatment was （ 23.38 ± 3.88 ） % , which was lower than that of the control group after treatment （ t = 9.93, P 〈 0.05 ）, the data of the two groups after treatment were lower than those before treatment,the differences were statistically significant （t = 9.16,9.29 ,all P 〈 0.05 ）. Conclusion Montelukast treatment of bronchial asthma can significantly improve symptoms and immune function of patients,it is worthy of clinical popularization and application.
出处
《中国基层医药》
CAS
2016年第1期4-7,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
孟鲁司特
支气管哮喘
免疫功能
Montelukast
Bronchial asthma
The immunefunction
